BioMarin's SWOT analysis: stock growth potential amid rare disease focus

BioMarin (BMRN) reported strong Q1 2025 results, with revenue of $745M and EPS of $1.13, exceeding estimates. Voxzogo sales are projected to reach $900-950M in 2025, driving overall revenue growth of 9-12%. While the company faces potential competition and regulatory challenges, management anticipates margin expansion and double-digit earnings growth through 2029, targeting over $4B in revenue by 2027.

Analysis

BioMarin Pharmaceutical Inc. (BMRN) demonstrated robust financial health in Q1 2025, reporting total revenues of $745 million and an EPS of $1.13, surpassing consensus estimates of $738 million and $0.97 respectively. This performance was underpinned by a significant 19.36% year-over-year revenue growth and an industry-leading gross profit margin of 81.01%. Management has reaffirmed its full-year 2025 revenue guidance of $3.1 billion to $3.2 billion, reflecting a 9-12% YoY increase, largely driven by its flagship product Voxzogo, which is projected to achieve $900 million to $950 million in sales, a 22-29% growth. The company's strategic initiatives include expanding Voxzogo's reach from 49 to over 60 countries by 2027 and exploring label expansions, alongside advancing its pipeline with key data readouts expected in H2 2025 for BMN 333 (achondroplasia) and BMN 351 (Duchenne muscular dystrophy). BioMarin aims for over $4 billion in total revenues by 2027, with operating margins guided to 32-33% in 2025 and a target of 40% by 2026, potentially leading to double-digit earnings growth through 2029. The company's strong financial standing is further evidenced by a perfect Piotroski Score of 9, a "GREAT" financial health rating from InvestingPro, and a current ratio of 5.52. Despite trading near its 52-week low with a P/E ratio of 20.52, which InvestingPro suggests may indicate undervaluation, BMRN faces potential headwinds from competition for Voxzogo, notably from Ascendis Pharma's TransCon CNP and BridgeBio's infigratinib, and inherent regulatory risks associated with pipeline progression and patent litigation.

Key Decisions for Investors

• Investors could consider the current valuation, near its 52-week low and flagged as potentially undervalued by InvestingPro, as an opportunity, while closely monitoring upcoming H2 2025 data readouts for BMN 333 and BMN 351 as significant catalysts.
• Monitor Voxzogo's sales trajectory, including its geographic expansion towards 60+ countries by 2027 and potential label expansions, as these are critical for achieving the company's $4 billion revenue target by 2027 and sustained growth.
• Closely assess the competitive landscape, particularly the progress of rival products from Ascendis Pharma and BridgeBio, and any developments in regulatory pathways or patent challenges, as these factors could materially impact BioMarin's market share and growth prospects.